{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:37:35Z","timestamp":1780400255567,"version":"3.54.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is the most common form of leukemia among adults in Western countries. Despite the introduction of targeted therapies, including first-line Bruton\u2019s tyrosine kinase inhibitor (BTKi) treatment, CLL remains largely incurable. Frequent disease relapses occur due to remaining treatment-resistant CLL cells, calling for novel therapies to eliminate minimal residual disease (MRD). Peptide-based vaccination targeting human leucocyte antigen (HLA)-presented CLL-associated antigens represents a promising, low-side-effect therapeutic option to optimize treatment responses and eliminate residual tumor cells by inducing an anti-leukemic immune response. The iVAC-XS15-CLL01 trial is an open-label, first-in-human (FIH) Phase I trial, evaluating the CLL-VAC-XS15 vaccine in CLL patients undergoing BTKi-based therapy. The vaccine was developed from HLA-presented CLL-associated antigen peptides, identified through comparative mass-spectrometry-based immunopeptidome analyses of CLL versus healthy samples in a previous study. To facilitate rapid and cost-effective deployment, vaccine peptides are selected for each patient from a pre-manufactured \u201cpeptide warehouse\u201d based on the patient\u2019s individual HLA allotype and CLL immunopeptidome. The trial enrolls 20 CLL patients, who receive up to three doses of the vaccine, adjuvanted with the toll-like-receptor (TLR) 1\/2 ligand XS15 and emulsified in Montanide ISA 51 VG. The primary objective of the iVAC-XS15-CLL01 trial is to assess the safety and immunogenicity of the CLL-VAC-XS15 vaccine. Secondary objectives are to evaluate the vaccine impact on MRD, progression-free survival, and overall survival, as well as comprehensive immunophenotyping to characterize vaccine-induced T-cell responses. This Phase I trial aims to advance CLL treatment by enhancing immune-mediated disease clearance and guiding the design of subsequent Phase II\/III trials to implement a new therapeutic strategy for CLL patients.<\/jats:p>","DOI":"10.3389\/fonc.2024.1441625","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:05:19Z","timestamp":1724648719000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1\/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens"],"prefix":"10.3389","volume":"14","author":[{"given":"Alexander","family":"Englisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hayn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas S.","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hackenbruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacine","family":"Maringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Nelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Denk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zieschang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510193331606","article-title":"Chronic lymphocytic leukemia","volume":"333","author":"Rozman","year":"1995","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep15030047","article-title":"How I manage chronic lymphocytic leukemia","volume":"15","author":"Nasnas","year":"2023","journal-title":"Hematol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11899-024-00726-x","article-title":"Frontline therapy of CLL-changing treatment paradigms","volume":"19","author":"Coombs","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705074","article-title":"Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid Malignancy following allogeneic haemopoietic stem cell transplantation","volume":"36","author":"Russell","year":"2005","journal-title":"Bone marrow Transplantat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"B9","article-title":"Spontaneous\u201d complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature","volume":"12","author":"Ribera","year":"1987","journal-title":"Blood Cells"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-498287","article-title":"Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies","volume":"122","author":"Hallek","year":"2013","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1074\/mcp.R120.002309","article-title":"The peptide vaccine of the future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705974","article-title":"Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia","volume":"12","author":"Nelde","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-3556","article-title":"Abstract 3556: Immunopeptidomics-guided tumor antigen warehouse design and first clinical application of a personalized peptide vaccine for prostate cancer","volume":"82","author":"Maringer","year":"2022","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-3555","article-title":"Abstract 3555: Immunopeptidomics-guided tumor antigen warehouse design for peptide-based immunotherapy in head and neck squamous cell carcinomas","volume":"82","author":"Schroeder","year":"2022","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194659","article-title":"Immunopeptidome diversity in chronic lymphocytic leukemia identifies patients with favorable disease outcome","volume":"14","author":"Marconato","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1023015","article-title":"Anti-PD-L1\/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV","volume":"12","author":"Klausen","year":"2022","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009164","article-title":"Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia","volume":"7","author":"Ujjani","year":"2023","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01500-1","article-title":"SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia","volume":"36","author":"Mellinghoff","year":"2022","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1038\/s41467-023-40758-0","article-title":"Phase I\/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency","volume":"14","author":"Heitmann","year":"2023","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s40425-019-0796-5","article-title":"A new synthetic toll-like receptor 1\/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer","volume":"7","author":"Rammensee","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1038\/s41467-022-33746-3","article-title":"The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma","volume":"13","author":"Bauer","year":"2022","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04232-5","article-title":"A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity","volume":"601","author":"Heitmann","year":"2022","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-60327-118-9_5","article-title":"SYFPEITHI: database for searching and T-cell epitope prediction","volume":"409","author":"Schuler","year":"2007","journal-title":"Methods Mol Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/104303402320138952","article-title":"The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope","volume":"13","author":"Olive","year":"2002","journal-title":"Hum Gene Ther"},{"key":"B26","article-title":"Full-length dominant-negative survivin for cancer immunotherapy","volume":"9","author":"Yu","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25601","article-title":"Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation","volume":"128","author":"Widenmeyer","year":"2011","journal-title":"Int J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2023.11.009","article-title":"Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults","volume":"139","author":"Tandler","year":"2024","journal-title":"Int J Infect Dis"},{"key":"B29","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.02017"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099366","article-title":"RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses","volume":"111","author":"Schmitt","year":"2008","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms\u2019 tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci United States Am"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1385","article-title":"Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I\/II trial","volume":"17","author":"Brunsvig","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4048","article-title":"Evaluation of safety, immunogenicity, and preliminary efficacy of PolyPEPI1018 off-the-shelf vaccine with fluoropyrimidine\/bevacizumab maintenance therapy in metastatic colorectal cancer (mCRC) patients","volume":"38","author":"Hubbard","year":"2020","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20941","article-title":"Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer","volume":"69","author":"Feyerabend","year":"2009","journal-title":"Prostate"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29909","article-title":"Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation","volume":"138","author":"Casalegno-Garduno","year":"2016","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142310","article-title":"Spontaneous immunity against the receptor tyrosine kinase ROR1 in patients with chronic lymphocytic leukemia","volume":"10","author":"Hojjat-Farsangi","year":"2015","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416389112","article-title":"HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)","volume":"112","author":"Kowalewski","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7472","DOI":"10.1038\/s41467-023-42692-7","article-title":"TOF(IMS) mass spectrometry-based immunopeptidomics refines tumor antigen identification","volume":"14","author":"Hoenisch Gravel","year":"2023","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.883989","article-title":"The importance of being presented: target validation by immunopeptidomics for epitope-specific immunotherapies","volume":"13","author":"Becker","year":"2022","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-866830","article-title":"The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy","volume":"133","author":"Bilich","year":"2019","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.233","article-title":"Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy","volume":"29","author":"Berlin","year":"2015","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0161","article-title":"Immunologic targets in AML","volume":"4","author":"Ritz","year":"2023","journal-title":"Blood Cancer Discovery"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/blood.V130.Suppl_1.5346.5346","article-title":"Definition and characterization of a peptide warehouse for the patient-individualized peptide vaccination study (iVAC-L-CLL01) after first line therapy of CLL","volume":"130","author":"Bilich","year":"2017","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.273","article-title":"HLA antigen changes in Malignant cells: epigenetic mechanisms and biologic significance","volume":"27","author":"Campoli","year":"2008","journal-title":"Oncogene"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1242544","DOI":"10.1080\/2162402X.2016.1242544","article-title":"Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia","volume":"5","author":"Cubillos-Zapata","year":"2016","journal-title":"Oncoimmunology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci United States Am"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-593137","article-title":"Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma","volume":"125","author":"Sagiv-Barfi","year":"2015","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J Immunother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1441625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:05:23Z","timestamp":1724648723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1441625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":53,"alternative-id":["10.3389\/fonc.2024.1441625"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1441625","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"article-number":"1441625"}}